Skip to main content
Equibles
RVTY logo

RVTY · Revvity, Inc. · Documents

Track RVTY — free

Use RVTY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RVTY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$158.23 +7.40 (+4.91%) Play latest call Q3 2026 earnings call transcript
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$17.32B
Shares
111.59M
Volume · Nov 6 729.31K Avg daily vol (3M) 1.89M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $2.86B up 3.7% 10-K filed Feb 24, 2026 Quarterly report FY2026 Q2 Revenue $729.69M up 1.3% 10-Q filed Aug 11, 2026 Latest results New Financial results 8-K filed Nov 3, 2026 Earnings call New Q3 2026 earnings call Held Nov 3, 2026
2026
Nov 3
Current report 8-K
Financial results, Other events

Revvity reported third-quarter revenue of $729 million and EPS from continuing operations of $0.56, raised 2026 pro forma guidance to $2.86 billion revenue and $5.40-$5.45 adjusted EPS, and agreed to sell its China immunodiagnostics assets for up to $200 million.

Read from the first part of this long document
Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jul 5
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $729.69M ▲ 1.3% Net income $51.82M ▼ 3.9% Diluted EPS $0.47 ▲ 2.2%
May 12
Quarterly report 10-Q FY2026 Q1, ended Apr 5
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $711.12M ▲ 7.0% Net income $40.72M ▼ 3.6% Diluted EPS $0.36 ▲ 2.9%
Mar 16
Proxy statement DEF 14A Meeting Apr 28, 2026
Proxy statement AI summary on its way
Mar 6
Proxy statement PRE 14A Meeting Apr 28, 2026
Proxy statement AI summary on its way
Feb 24
Annual report 10-K FY2025, ended Dec 28
Annual report for FY2025 AI summary on its way
Revenue $2.86B ▲ 3.7% Net income $241.2M ▼ 10.8% Diluted EPS $2.07 ▼ 5.9%
2025
Nov 4
Quarterly report 10-Q FY2025 Q3, ended Sep 28
Quarterly report for FY2025 Q3
Revenue $698.95M ▲ 2.2% Net income $46.65M ▼ 50.6% Diluted EPS $0.40 ▼ 48.1%
Aug 5
Quarterly report 10-Q FY2025 Q2, ended Jun 29
Quarterly report for FY2025 Q2
Revenue $720.28M ▲ 4.1% Net income $53.95M ▼ 2.6% Diluted EPS $0.46 ▲ 2.2%
May 6
Quarterly report 10-Q FY2025 Q1, ended Mar 30
Quarterly report for FY2025 Q1
Revenue $664.76M ▲ 2.3% Net income $42.24M ▲ 62.4% Diluted EPS $0.35 ▲ 66.7%
Feb 25
Annual report 10-K FY2024, ended Dec 29
Annual report for FY2024
Revenue $2.76B ▲ 0.2% Net income $270.39M ▼ 61.0% Diluted EPS $2.20 ▼ 60.4%
2024
Nov 6
Quarterly report 10-Q FY2024 Q3, ended Sep 29
Quarterly report for FY2024 Q3
Revenue $684.05M ▲ 2.0% Net income $94.37M ▲ 893.7% Diluted EPS $0.77 ▲ 862.5%
Aug 6
Quarterly report 10-Q FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $691.69M ▼ 2.5% Net income $55.36M ▲ 55.7% Diluted EPS $0.45 ▲ 60.7%
May 7
Quarterly report 10-Q FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Revenue $649.92M ▼ 3.7% Net income $26.01M ▼ 95.4% Diluted EPS $0.21 ▼ 95.3%
Showing 1–50 of 151 documents
Key facts CIK 31791 CUSIP 714046109 13F (30d) 288 filings 250 filers Visit website Investor relations